Sun Life Reports 10% Underlying EPS Growth and Dividend Hike Despite Reported Profit Hit

What happened

Sun Life Financial's Q3 2026 earnings call revealed a 10% year-over-year increase in underlying earnings per share and a raised quarterly dividend, highlighting the resilience of its core operations. This growth was achieved despite reported profit being weighed down by market-related losses, acquisition costs, and restructuring expenses, which are non-recurring in nature. The underlying performance aligns with the DeepValue thesis that Sun Life's capital-light insurance and asset management businesses are driving robust earnings growth, particularly in Asia and wealth management. However, the earnings call did not provide clarity on the key risks identified in the master report: U.S. group benefits morbidity normalization and MFS net outflows, leaving those concerns unaddressed. The dividend increase signals management's confidence in future cash flows, supporting the thesis's emphasis on dividend durability, but the one-time charges suggest reported earnings remain volatile.

Implication

The double-digit underlying EPS growth and dividend raise reinforce the base-case assumption that Sun Life can deliver mid-single-digit or better EPS growth, supporting the POTENTIAL BUY rating. However, the presence of market-related losses, acquisition costs, and restructuring expenses indicates that reported earnings will continue to be noisy, and investors should focus on underlying metrics as the master report does. The lack of commentary on U.S. group morbidity and MFS flows in the news summary means the two primary risks to the thesis remain unresolved; investors should await the full earnings release for segment-level detail. If underlying ROE remains above 18% and U.S. group shows improvement in the coming quarters, the bull case becomes more likely, but if those issues persist, the bear case gains weight. Given that the stock has likely moved since the master report's January reference price of $63.22, investors should reassess valuation relative to the $70 trim threshold and $58 entry level before making new decisions.

Thesis delta

The thesis remains intact but with increased confidence in the core growth engine: the 10% underlying EPS growth exceeds the base-case expectation of mid-single-digit growth, supporting the premium valuation if sustained. However, the unresolved U.S. group morbidity and MFS outflows remain critical swing factors, and the one-time charges in reported profit do not alter the fundamental risk profile. The dividend raise reinforces the margin of safety from income, but does not eliminate the need for monitoring the key operational checkpoints outlined in the master report.